The Role of Interferon-α in the Management of Myelomatosis
- 1 April 1992
- journal article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 6 (2) , 395-405
- https://doi.org/10.1016/s0889-8588(18)30352-6
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Influence of interferon on antibody production and viability of malignant cells from patients with multiple myelomaEuropean Journal of Haematology, 2009
- Interferon therapy during the plateau phase of multiple myeloma: An update of the Swedish studyEuropean Journal of Cancer and Clinical Oncology, 1991
- Alpha‐2a‐interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myelomaBritish Journal of Haematology, 1990
- Combination of interferon and dexamethasone in refractory multiple myelomaHematological Oncology, 1990
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- Effect of interferon alpha‐2b in advanced multiple myelomaJournal of Internal Medicine, 1990
- Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- Development of transformed phenotype induced by a human ras oncogene is inhibited by interferonBiochemical and Biophysical Research Communications, 1985
- Induction and kinetics of natural killer cells in humans following interferon therapyNature, 1979
- INTERFERON THERAPY IN MYELOMATOSISThe Lancet, 1979